Pomerantz Law Firm Investigates Cumberland Pharmaceuticals Following Clinical Trial Results and Stock Decline
Pomerantz LLP has launched an investigation into Cumberland Pharmaceuticals Inc. (CPIX) regarding potential securities fraud or unlawful business practices. The probe follows the company's October 23, 2026, announcement of Phase 2a ASSIST-SSc clinical trial results for its oral drug, ifetroban, intended for patients with systemic sclerosis. While Cumberland reported that the drug was well tolerated and met safety objectives, the pilot study failed to provide a clear efficacy signal. Due to limited disease progression in both treatment and placebo groups, the 41-patient trial lacked sufficient statistical power to determine effectiveness. Following these results, CPIX shares plummeted 48.76%, closing at $4.35 on October 26, 2026.
Tickers: $CPIX
Topics: class action lawsuit clinical trial results securities fraud investigation stock price decline
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates Iovance Biotherapeutics Following Clinical Trial Data Discrepancy (2 articles)